Oculis Completes Phase 3 Trials for DME Eye Drop, Aims for Q4 2026 NDA Submission

Event summary

  • Oculis completed the last patient visit in its Phase 3 DIAMOND trials for OCS-01 eye drops, treating diabetic macular edema (DME).
  • Topline results from the 800+ patient trials are expected in June 2026, with a potential NDA submission in Q4 2026.
  • OCS-01 aims to be the first non-invasive topical treatment for DME, addressing unmet needs for early intervention and inadequate responders to current therapies.
  • The DIAMOND program consists of two Phase 3, double-masked, randomized, multi-center trials evaluating OCS-01 over 52 weeks.

The big picture

Oculis' completion of the Phase 3 DIAMOND trials for OCS-01 represents a critical milestone in the development of a non-invasive treatment for diabetic macular edema. With an estimated 1 million untreated or underserved DME patients in the U.S., OCS-01 has the potential to transform the treatment paradigm. The strategic positioning of OCS-01 as a topical eye drop could significantly reshape how DME is managed, particularly for patients with mild vision loss or inadequate responses to current therapies.

What we're watching

Regulatory Approval
Whether the topline results in June 2026 will support a successful NDA submission in Q4 2026.
Market Potential
The pace at which OCS-01 can capture the significant opportunity in the $3 billion U.S. DME market.
Competitive Positioning
How OCS-01 will differentiate itself from existing invasive therapies and address the unmet needs of DME patients.